Maternal Use of Drugs for Nausea and Vomiting in Pregnancy and Infant Congenital Malformations

  • Bengt Källén


Use of drugs for nausea and vomiting in pregnancy (NVP) is associated with a tendency to a slightly reduced risk for congenital malformations. This is probably not an effect of the drugs but a sign that moderate NVP may be a result of a well-functioning placenta. The only exception concerns ondansetron which has been linked to an increased risk for cardiovascular defects, notably septum defects. This association is not definitely proved but it may be a good idea to avoid this drug during the first trimester. This, of course, does not prevent its use later in pregnancy, when the serious condition of hyperemesis gravidarum usually occurs.


  1. Anderka M, Mitchell AA, Louik C, Werler MM, Hernández-Dias S, Rasmussen SA, The National Birth Defects Prevention Study. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol. 2012;94:22–30.CrossRefGoogle Scholar
  2. Andersen JT, Jimenez-Solem E, Andersen NL, Poulsen HE. Ondansetron use in early pregnancy and the risk of congenital malformations—a registry based nationwide cohort study. Montreal: International Society of Pharmaco-Epidemiology; 2013. Abstract 25. Pregnancy session 1.Google Scholar
  3. Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy. Eur J Clin Pharmacol. 2005;61:899–906.CrossRefGoogle Scholar
  4. Berkovitch M, Mazzola P, Greenberg R, Elbirt D, Addis A, Schuler-Faccini L, Merlob P, Arnon J, Stahl B, Magee L, Morelli M, Ornoy A. Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. Am J Perinatol. 2002;19:311–6.CrossRefGoogle Scholar
  5. Brent BI. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Reprod Toxicol. 1995;9:337–49.CrossRefGoogle Scholar
  6. Colvin L, Gill AW, Slack-Smith L, Stanley FJ, Bower C. Off-label use of ondansetron in pregnancy in Western Australia. Biomed Res Int. 2013;2013:909860.CrossRefGoogle Scholar
  7. Czeizel AE, Vargha P. A case-control study of congenital abnormality and dimenhydrinate usage during pregnancy. Arch Gynecol Obstet. 2005;271:113–8.CrossRefGoogle Scholar
  8. Danielsson B, Norstedt-Wikner B, Källén B. Use of ondansetron during pregnancy and congenital malformations. Reprod Toxicol. 2014;50:134–7.CrossRefGoogle Scholar
  9. Edlavitch SA. Publishing negative findings and the challenge of avoiding type II errors in studies of suspected teratogens: example of a recent ondansetron publication. Reprod Toxicol. 2017;67:125–8.CrossRefGoogle Scholar
  10. Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP, Koreon G. The safety of ondansetron for nausea and vomiting of pregnancy; a prospective comparative study. BJOG. 2004;111:940–3.CrossRefGoogle Scholar
  11. Eskenazi B, Bracken MB. Bendectin (Debendox) as a risk factor for pyloric stenosis. Am J Obstet Gynecol. 1982;144:919–24.CrossRefGoogle Scholar
  12. Fejzo MS, MacGibbon KW, Mullin PM. Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States. Reprod Toxicol. 2016;62:87–9.CrossRefGoogle Scholar
  13. Fiaschi L, Nelson-Piercy C, Tata LJ. Hospital admission for hymeremesis gravidarum: a nationwide study of occurrence, recurrence and risk factors among 8.2 million pregnancies. Hum Reprod. 2016;31:1675–84.CrossRefGoogle Scholar
  14. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group; 1977.Google Scholar
  15. Källén B, Mottet I. Delivery outcome after the use of meclizine in early pregnancy. Eur J Epidemiol. 2003;18:665–9.CrossRefGoogle Scholar
  16. Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med. 2009;360:2528–35.CrossRefGoogle Scholar
  17. McBride WG. An aetiological study of drug ingestion by women who gave birth to babies with cleft palate. Aust N Z J Obstet Gynaecol. 1969;9:103–4.CrossRefGoogle Scholar
  18. McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects. I. A meta-analysis of the epidemiologic studies. Teratology. 1994;40:27–37.CrossRefGoogle Scholar
  19. Milkovich L, van der Berg BJ. An evaluation of teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol. 1983;125:244–8.CrossRefGoogle Scholar
  20. Pasternak B, Svanström H, Mølgaard-Nielsen D, Melbye M, Hviid A. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA. 2013a;310:1601–11.CrossRefGoogle Scholar
  21. Pasternak B, Svanström H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med. 2013b;368:814–23.CrossRefGoogle Scholar
  22. Sørensen HT, Nielsen GL, Chrinstensen K, Tage-Jensen U, Ekbom A, Baron J, The Euromap Study Group. Birth outcome following maternal use of metoclopramide. Br J Pharmacol. 2000;49:264–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Bengt Källén
    • 1
  1. 1.Tornblad Institute for Comparative EmbryologyLund UniversityLundSweden

Personalised recommendations